{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-037602","form_type":"8-K","ticker":null,"cik":"0001651407","company_name":"Checkpoint Therapeutics, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.983772+00:00","generated_at":"2026-06-04T09:04:30.750533+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Checkpoint Therapeutics reports FY2023 net loss of $51.8M; BLA resubmission for cosibelimab targeted by mid-2024","bullets":["Net loss $51.8M ($3.17 per share) vs $62.6M ($7.09) in FY2022; no revenue.","Cash and equivalents $4.9M at Dec 31, 2023; Jan 2024 offering added $14.0M gross.","R&D expenses $43.6M, down from $49.8M; G&A flat at $8.7M.","CRL from FDA in Dec 2023 only cited CMO inspection issues; resubmission planned mid-2024.","Appointed Dr. Amit Sharma to board; raised ~$47.6M via offerings in 2023-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-037602","json":"https://secwatch.observer/filing/0001104659-24-037602.json","markdown":"https://secwatch.observer/filing/0001104659-24-037602.md","text":"https://secwatch.observer/filing/0001104659-24-037602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924037602/0001104659-24-037602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924037602/tm249333d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:04:30.750533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc85910f944e254e6f471d9b158e7812655feb79","claim":"Checkpoint Therapeutics, Inc. reported full-year ended December 31, 2023 results: net income Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million, EPS ($3.17 per share).","evidence_excerpt":"Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651407/000110465924037602/0001104659-24-037602-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year ended December 31, 2023"},{"label":"Net income","value":"Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million"},{"label":"EPS","value":"($3.17 per share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}